Signadori Bio announced the completion of a seed extension financing round, bringing the company’s total funding to €11.1 million. The latest investment included participation from Taiho Ventures along with existing investors Sofinnova Partners and Invivo Partners.
The company said the funding will support the advancement of its lead program, SiB-2101, toward nomination as a lead candidate, continued development of its proprietary in vivo monocyte engineering platform, and expansion of its scientific and operational teams.
Signadori Bio is developing an off-the-shelf immunotherapy platform that engineers monocytes in vivo to enhance anti-tumor immune activity. The company aims to address limitations of current immunotherapies and autologous cell therapies, particularly in solid tumors and immunosuppressive tumor microenvironments.
The company’s approach is to harness the innate immune system using gene-modified monocytes engineered directly within patients. Signadori Bio was founded by Dr. Jean-Luc Perfettini and Professor Nathalie Chaput based on research conducted at Gustave Roussy.
Taiho Ventures said the company’s preclinical data and scientific foundation position it to address unmet needs in solid tumor treatment, while Sofinnova Partners highlighted Signadori Bio’s progress validating its platform and p21-driven monocyte reprogramming approach.
Signadori Bio is headquartered in Paris and operates as a preclinical-stage biopharmaceutical company focused on next-generation monocyte immunotherapies for cancer treatment.
KEY QUOTES:
“This financing represents an important milestone for Signadori Bio as we continue to build on our promising preclinical data and advance our platform toward the clinic. Our approach to in vivo engineering of monocytes has the potential to unlock a new class of immunotherapies that are more accessible, scalable, and effective for patients with solid tumours. We are delighted to welcome Taiho Ventures alongside our existing investors, Sofinnova Partners and Invivo Partners.”
Dr. Selwyn Ho, Chief Executive Officer, Signadori Bio
“Signadori Bio is advancing a highly differentiated strategy in immuno-oncology by targeting monocytes and leveraging in vivo engineering. The company’s compelling preclinical data and strong scientific foundation position it well to address significant unmet needs in solid tumours. We are excited to support the team in this next phase of development.”
Seiji Miyahara, Partner And Senior Investment Director, Taiho Ventures
“Since inception, Signadori Bio has made strong progress in validating its platform and demonstrating the therapeutic potential of p21-driven monocyte reprogramming. This financing will enable the company to accelerate its development strategy and move closer to clinical translation.”
Matthieu Coutet, Chair Of The Board, Signadori Bio And Partner, Sofinnova Partners
